SeaCrest Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

SeaCrest Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-109	Closed	-$17K	–	1075
2022 Q2	$17K	Buy	+109	New	+$16.8K	﹤0.01%	1540
2019 Q2	–	Sell	-100	Closed	-$14K	–	1198
2019 Q1	$14K	Hold	100	–	–	﹤0.01%	1416
2018 Q4	$12K	Sell	100 -35	-26%	-$5.19K	﹤0.01%	1435
2018 Q3	$23K	Hold	135	–	–	﹤0.01%	1324
2018 Q2	$23K	Hold	135	–	–	﹤0.01%	1305
2018 Q1	$20K	Hold	135	–	–	﹤0.01%	1331
2017 Q4	$18K	Buy	+135	New	+$18.7K	﹤0.01%	1375

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

SeaCrest Wealth Management's JAZZ Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 109 shares — an estimated $17K sold.

SeaCrest Wealth Management first reported a position in JAZZ in Q4 2017 and held it in 7 quarters. The position peaked at $23K in Q3 2018. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

SeaCrest Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 109 Jazz Pharmaceuticals shares in Q3 2022, an estimated $17K.
SeaCrest Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 7 quarters.
SeaCrest Wealth Management's Jazz Pharmaceuticals position peaked at $23K in Q3 2018.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.